


## Balsalazide sodium hydrate

<b>Cat. No.:</b>	HY-B0667A
<b>CAS No.:</b>	150399-21-6
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>17</sub> N <sub>3</sub> Na <sub>2</sub> O <sub>8</sub>
<b>Molecular Weight:</b>	437.31
<b>Target:</b>	Interleukin Related; STAT
<b>Pathway:</b>	Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (285.84 mM; Need ultrasonic)  
H<sub>2</sub>O : 100 mg/mL (228.67 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.2867 mL	11.4335 mL	22.8671 mL
	5 mM	0.4573 mL	2.2867 mL	4.5734 mL
	10 mM	0.2287 mL	1.1434 mL	2.2867 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Balsalazide sodium hydrate could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.		
<b>IC<sub>50</sub> &amp; Target</b>	IL-6	IL-1	STAT3
<b>In Vivo</b>	<p>At the endpoint, the protein production of MIP-1<math>\beta</math>, MCP-1, IL-6, and IL-10 in the colon tissues decrease in concordance with the plasma concentrations of the cytokines. The drug-treated groups reveal lower expression of p-STAT3 compared to the CAC group. In addition, BCL2 decreases and BAX increases markedly in the BSZ+VSL#3 group<sup>[1]</sup>. Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>		

### REFERENCES

[1]. Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61.

---

[2]. Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49(6): p. 783-789.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA